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Two-Year Clinical Follow-Up After Sirolimus-Eluting
Versus Bare-Metal Stent Implantation Assisted
by Systematic Glycoprotein IIb/IIIa Inhibitor
Infusion in Patients With Myocardial Infarction
Results From the STRATEGY Study
Marco Valgimigli, MD, PHD,*† Gianluca Campo, MD,* Chiara Arcozzi, MD,*
Patrizia Malagutti, MD,* Roberto Carletti, MD,* Fabrizio Ferrari, MD,* Dario Barbieri, MD,*
Giovanni Parrinello, PHD,‡ Gianfranco Percoco, MD,* Roberto Ferrari, MD, PHD,*†
Ferrara, and Brescia, Italy
Objectives We sought to investigate whether the previously reported midterm clinical benefit of planned sirolimus-eluting
stent (SES) implantation in patients with ST-segment elevation myocardial infarction (STEMI) was maintained
over a 24-month time period. Moreover, the distribution of clinical events in relation to thienopyridine discontinu-
ation was thoroughly investigated.
Background No randomized data are currently available on the safety/benefit profile of SES in this subset of patients beyond
12 months.
Methods Between March 2003 and April 2004, 175 patients with STEMI were randomly allocated to tirofiban infusion
followed by SES or abciximab plus bare-metal stent (BMS). Complete follow-up information up to 720 days was
available for all patients.
Results The cumulative incidence of death, myocardial infarction (MI), or target vessel revascularization (TVR) remained
lower in the tirofiban-SES compared with the abciximab-BMS group at 2 years (24.2% vs. 38.6%, respectively;
hazard ratio [HR] 0.56 [95% confidence interval (CI) 0.33 to 0.98]; p  0.038). The composite of death/MI was
similar in the tirofiban-SES (16.1%) and the abciximab-BMS groups (20.5%, HR 0.77 [95% CI 0.38 to 1.55]; p 
0.43) while the need for TVR was markedly reduced (9.8% vs. 25.5%, respectively; HR 0.34 [95% CI 0.16 to
0.77]; p  0.01) in the tirofiban-SES arm. The rate of confirmed, probable, or possible stent thrombosis did not
differ in the 2 groups, nor the incidence of death/MI after thienopyridine discontinuation.
Conclusions The midterm clinical benefit of planned SES implantation assisted by tirofiban infusion in STEMI patients was
mainly carried over after 2 years with no overall excess of late adverse events after thienopyridine discon-
tinuation. (J Am Coll Cardiol 2007;50:138–45) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.029s
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where are growing concerns as to the possibility that the
afety and clinical benefit of drug-eluting stent (DES)
mplantation may not be sustained over time, especially
hen unselected patient/lesion subsets have been treated
1–3).
While the available clinical follow-up of the pivotal trials
hat led to the approval of the sirolimus-eluting (SES) or
aclitaxel-eluting stent in Europe and the U.S. failed to
rom the *Institute of Cardiology, University of Ferrara, Ferrara, Italy; †Cardiovas-
ular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago, Brescia,
taly; and ‡Medical Statistics Unit, University of Brescia, Brescia, Italy.i
Manuscript received October 31, 2006; revised manuscript received December 11,
006, accepted January 1, 2007.how an increase in adverse events in patients treated with
ES (4–8), a rising amount of reports describe the occur-
ence of late stent thrombosis (ST) (9–13) or even resteno-
is (14,15) after the conventional 8- to 12-month follow-up
n a probably small but still undefined proportion of pa-
ients. Thus, long-term clinical surveillance, especially of
igh-risk patients after DES implantation, is particularly
arranted.
See page 146
In the recently published PREMIER (Prospective Reg-
stry Evaluating Myocardial Infarction: Events and Recov-
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July 10, 2007:138–45 2-Year Outcome of the STRATEGY Trialry) registry (13), specific concerns were raised regarding the
nrestricted use of DES in patients with ST-segment
levation myocardial infarction (STEMI), where compli-
nce to long-term treatment with thienopyridines cannot be
etermined up front. In the first randomized trial to
valuate the benefit of DES assisted by glycoprotein IIb/IIIa
nfusion in STEMI patients, a clinical benefit in terms of
eintervention in the previously instrumented artery has
een reported at 8 months in the group assigned to SES
16). Consistent information has been more recently re-
orted by the industry-driven TYPHOON (Trial to Assess
he Use of the Cypher Stent in Acute Myocardial Infarction
reated With Angioplasty) study at 1 year (17). No ran-
omized data are currently available on the safety/benefit
rofile of SES in this subset of patients at longer-term
ollow-up. We sought to investigate whether the midterm
linical benefit of planned SES implantation observed in the
TRATEGY (Single High-Dose Bolus Tirofiban and
irolimus Eluting Stent Versus Abciximab and Bare Metal
tent In Acute Myocardial Infarction) trial was maintained
ver a 24-month time period. Moreover, the distribution of
linical events in relation to thienopyridine discontinuation
as thoroughly investigated.
ethods
tudy design and medications. The design of the study
as been previously reported (16,18). Briefly, patients with
TEMI were randomly assigned before obtaining initial
ngiogram to single high-dose bolus tirofiban infusion (25
g/kg/3 min and 0.15 g/kg/min for 18 to 24 h) followed
y SES implantation or abciximab (bolus of 0.25 g/kg/3
in with 0.125 g/kg/min for 12 h) and bare-metal stent
BMS) implantation. All patients received aspirin (250 mg
ntravenous followed by 100 mg/day), clopidogrel (300 mg
ollowed by 75 mg/day), and heparin (50 to 70 U/kg with
dditional bolus if necessary) according to current
uidelines.
tudy population and end points definition. Between
arch 6, 2003 and April 23, 2004, 175 patients with
TEMI were included. Three patients in the tirofiban-SES
roup and 5 in the abciximab-BMS group did not undergo
ercutaneous coronary intervention (PCI). Overall, 74
85%) patients in the tirofiban-SES and 77 (88%) in the
bciximab-BMS arm received the protocol-mandated treat-
ent combination. Patients were considered for 6-month
ngiographic follow-up if protocol-mandated PCI had been
ttempted. The primary end point was freedom, at 8
onths after randomization, from death, nonfatal myocar-
ial infarction (MI), stroke, and binary restenosis. Patients
ere scheduled to undergo clinical follow-up at 30 days and
hen every 6 months from enrollment. The 2-year analysis
as prespecified per the protocol; follow-up information
as planned to be collected every year until 5 after random-
zation. All deaths were considered cardiac unless an un-
quivocal noncardiac cause could be established. A definite Siagnosis of MI after normaliza-
ion of cardiac markers was made
f there was documentation of
ew abnormal Q waves (accord-
ng to the Minnesota code) or a
onfirmed elevation above upper
imit of normal of creatine ki-
ase/creatine kinase-MB or tro-
onin I or T in at least 1 blood
ample.
A definite ST was considered
o have occurred based on: 1) an
ngiographic documentation of
arget vessel occlusion or both
educed Thrombolysis in Myo-
ardial Infarction flow and the
resence of thrombus in the
tented region coupled with at
east one of the following: a) new
cute onset of ischemic symp-
oms at rest; b) new ischemic
lectrocardiogram changes sug-
estive of acute ischemia; or c)
ypical rise and fall in cardiac biomarkers; or 2) evidence of
ecent thrombus within the stent determined at autopsy or
ia examination of tissue retrieved after thrombectomy.
Probable ST was defined as any unexplained death within
he first 30 days or any MI with evidence of acute ischemia
n the territory of the implanted stent without angiographic
onfirmation of ST and in the absence of any other obvious
ause.
Possible ST was considered to have occurred with any
nexplained death from 30 days after intracoronary stenting
ntil end of trial follow-up.
Unlike previous definitions (8), freedom from interim
arget vessel revascularization (TVR) was not a prerequisite
or satisfying the diagnosis of confirmed or possible ST.
his employed broad definition of ST is post hoc and in
eeping with recently proposed Academic Research Con-
ortium classification (19).
tatistical analysis. All analyses were conducted according
o the intention-to-treat principle when not otherwise
tated. Discrete data were summarized as frequencies,
hereas continuous data were expressed as mean  SD.
isher exact test (categorical variables) and Student t test
continuous variables) were employed to analyze differences
etween the 2 study arms. Event-free survival curves were
enerated by the Kaplan-Meier method, and survival be-
ween groups was compared using the log-rank test. Hazard
atios (HRs) with 95% confidence intervals (CIs) were
alculated using a proportional hazards model (PHM).
The proportionality assumptions for PHM were checked
y visual estimation after plotting the log cumulative hazard
ersus (log) time at follow-up after index procedure and by
pplying a test for nonproportional hazards using the
Abbreviations
and Acronyms
BMS  bare-metal stent
CI  confidence interval
DES  drug-eluting stent
HR  hazard ratio
MACE  major adverse
cardiovascular events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PHM  proportional
hazards model
SES  sirolimus-eluting
stent
ST  stent thrombosis
STEMI  ST-segment
elevation myocardial
infarction
TVR  target vessel
revascularizationchoenfeld residuals as previously described (20). Moreover,
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2-Year Outcome of the STRATEGY Trial July 10, 2007:138–45o formally investigate the relation of thienopyridine dis-
ontinuation to events, we performed a multivariable PHM
ncluding treatment with ticlopidine or clopidogrel as a
ime-dependent variable. A 2-sided p value 0.05 was
onsidered significant for all tests. All analyses were per-
ormed using STATISTICA version 6.1 (Statsoft Inc.,
ulsa, Oklahoma) or R-language (R Foundation, Vienna,
ustria).
esults
s previously reported, both groups had similar baseline
linical and angiographic characteristics, procedural factors,
ith the only exception of a smaller nominal stent diameter
n the SES group, and 30-day results. Complete follow-up
nformation up to 720 days was available for all patients.
As compared with the previously reported clinical events
t 8 months, we observed 13 new major adverse cardiovas-
ular event (MACE) episodes, 6 of which occurred in
atients assigned to receive tirofiban  SES. In this group,
additional patients died, 2 of them from cancer and 1 from
atal reinfarction, 1 patient had a nonfatal reinfarction, and
patients underwent coronary artery bypass grafting for
ngiographically confirmed disease progression at coronary
ites distant from the previously stented segments. In the
roup allocated to abciximab and bare-metal stenting, 4
dditional patients died, 2 from cancer, 1 from fatal pulmo-
ary infection, and 1 due to sudden death, and 3 patients
nderwent TVR for angiographically confirmed disease
rogression in 1 case and for stent reocclusion in 2 patients
ho had previously refused to undergo 6-month angio-
raphic follow-up.
The cumulative incidence of MACE (death, MI, or
VR) remained lower in the tirofiban-SES compared with
he abciximab-BMS group at 2 years (24.2% vs. 38.6%,
espectively; HR 0.56 [95% CI 0.33 to 0.98]; p  0.038)
Fig. 1A, Table 1). Overall, the composite of death/MI was
imilar in the tirofiban-SES (16.1%) and the abciximab-
MS group (20.5%, HR 0.77 [95% CI 0.38 to 1.55]; p 
.43) (Fig. 1B, Table 1), while the need for TVR remained
arkedly reduced (9.8% vs. 25.5%, respectively; HR 0.34
95% CI 0.16 to 0.77]; p  0.01) in the tirofiban-SES
roup (Fig. 1C, Table 1).
Within 30 days, 2 definite, angiographically confirmed
T occurred, both in the abciximab  BMS group. In one
f the patients, who suffered from diabetes, a SES had been
mplanted as a protocol violation. Between 30 and 720 days,
here were no cases of definite ST, while probable ST
ccurred in 1 patient in the tirofiban  SES (1.1%) and in
cases in the abciximab  BMS (2.2%) group. There were
additional episodes of possible ST in each group (Table 2).
hus, the cumulative incidence of definite, probable, or
ossible ST were 0%, 1.1%, and 2.2% in the tirofiban 
ES arm versus 2.2% (p 0.49), 2.2% (p 0.99), and 2.2%
p  0.99) in the abciximab  BMS group, respectively
Tables 1 and 2).Figure 1 Event-Free Survival After Randomization
Two-year adverse events in patients allocated to tirofiban  sirolimus-eluting
stent (tirofiban  sirolimus-eluting stent [SES] group) and in patients random-
ized to abciximab infusion plus bare-metal stenting (abciximab  bare-metal
stent [BMS] group). Cumulative risk of major adverse events (A), death or myo-
cardial infarction (B), and target vessel revascularization (C).
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July 10, 2007:138–45 2-Year Outcome of the STRATEGY TrialAt per-protocol analysis, after exclusion of those patients
here protocol violations took place, the overall incidence of
efinite, probable, or possible ST was 4% in the tirofiban 
ES versus 5.2% in the abciximab  BMS group (p  0.99).
At per-stent analysis, the cumulative incidence of defi-
ite, probable, or possible ST was 6.6% versus 4.8% (p 
.44) in the SES and BMS groups, respectively.
The mean duration of dual antiplatelet treatment (either
lopidogrel or ticlopidine and aspirin) was 182  92 days in
he tirofiban SES versus 155 105 days in the abciximab
BMS group (p  0.073). The multivariable proportional
0-Day, 12- and 24-Month Outcome
Table 1 30-Day, 12- and 24-Month Outcome
Variables Abciximab BMS (n  88)
30-day outcome, n (%)
Death 3 (3)
Re-AMI 3 (3)
Urgent TVR 3 (3)
CVA 0 (0)
Stent thrombosis† 2 (2)
Death/re-AMI 6 (7)
Death/re-AMI/urgent TVR 7 (8)
12-month outcome, n (%)
Death 8 (9)
Re-AMI 8 (9)
TVR 18 (20)
Definite stent thrombosis† 2 (2)
Probable stent thrombosis 2 (2)
Possible stent thrombosis 1 (1)
Any stent thrombosis 5 (6)
Death/re-AMI 15 (17)
Death/re-AMI/TVR 28 (32)
24-month outcome, n (%)
Death 12 (14)
Re-AMI 8 (9)
TVR 21 (24)
Stroke 0 (0)
Definite stent thrombosis† 2 (2)
Probable stent thrombosis 2 (2)
Possible stent thrombosis 2 (2)
Any stent thrombosis 6 (7)
Death/re-AMI 18 (20)
Death/re-AMI/TVR 34 (39)
Death/re-AMI/CVA/restenosis 41 (46)
By Fisher exact test for 30-day outcomes and for stent thrombosis or composite end points inc
pisodes were angiographically confirmed.
BMS bare-metal stent; CI confidence interval; CVA cerebrovascular accident; HR hazard
essel revascularisation.azard model including dual antiplatelet treatment as time- dependent variable showed only a trend for the use of
hienopyridines to be protective with respect to major
ardiac adverse events at follow-up (HR 0.74 [95% CI 0.36
o 1.53]; p  0.42).
When the cumulative incidence of death or nonfatal
I was compared between the 2 groups starting from the
ime of thienopyridine discontinuation, the event rate
as again similar in the tirofiban  SES (7.7%) versus
he abciximab  BMS group at 2 years (7%, HR 1.07
95% CI 0.33 to 3.57]; p  0.90) (Fig. 2). It is
oteworthy that 4 events per group clustered within 30
B Tirofiban SES (n  87) HR (95% CI) p Value*
2 (2) — 0.99
1 (1) — 0.62
1 (1) — 0.62
0 (0) — 0.99
0 (0) — 0.24
3 (3) — 0.49
3 (3) — 0.33
7 (8) HR 0.77
[95% CI: 0.29–2.1]
0.59
6 (7) HR 0.75
[95% CI: 0.26–2.22]
0.60
6 (7) HR 0.30
[95% CI: 0.12–0.77]
0.01
0 (0) — 0.24
1 (1) — 0.99
2 (2) — 0.99
3 (3) 0.63
[95% CI: 0.15–2.5]
0.50
11 (13) 0.71
[95% CI: 0.34–1.5]
0.39
16 (18) HR 0.53
[95% CI: 0.28–0.92]
0.04
10 (11) HR 0.84
[95% CI: 0.36–1.96]
0.66
7 (8) HR 0.82
[95% CI: 0.31–2.4]
0.77
8 (9) HR 0.34
[95% CI: 0.16–0.77]
0.01
0 (0) — 0.99
0 (0) — 0.49
1 (1) — 0.99
2 (2) — 0.99
3 (3) 0.51
[95% CI: 0.13–2.1]
0.34
14 (16) HR 0.77
[95% CI: 0.38–1.55]
0.56
21 (24) HR 0.56
[95% CI: 0.33–0.98]
0.038
21 (24) — 0.002
inary restenosis and by Cox regression analysis for remaining 12- and 24-month events; †both
re-AMI reinfarction; SES sirolimus-eluting stent; SHBD single high bolus dose; TVR targetSHD
luding bays of therapy discontinuation.
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hile the risk of ST after BMS decreases rapidly after 2 to
weeks, delayed endothelial coverage, endothelial dysfunc-
ion, and positive vessel remodeling are thought to prolong
he window of vulnerability to acute, subacute, or late
hrombotic stent closure after DES implantation. Conse-
uently, recommendations for currently approved DES
nclude a minimum of 3 to 6 months of thienopyridine
herapy, in addition to long-term aspirin use.
After the pivotal reports describing the occurrence of late
T after DES implantation, especially in the setting of
essation of antiplatelet therapy (9,12), consistent findings
ave been echoed by several different groups (1,3), raising a
ote of caution regarding the safety/efficacy profile of this
ew coronary technology when employed in unselected
atient/lesion subsets. More recently, the BASKET-LATE
Basel Stent Cost-Effectiveness Trial—Late Thrombotic
vents) trial reported a trend towards an increase of death
r nonfatal MI in patients treated with DES after thieno-
linical and Procedural Characteristics of Patients With Confirmed
Table 2 Clinical and Procedural Characteristics of Patients Wit
Patient No.
(Sub)acute
#22 #174 #115
Age, yrs 64 57 82
Gender M M M
Diabetes Yes No No
Previous MI No No No
Creatinine clearance (ml/min) 64.2 91.3 37.2
IRA LAD RCA RCA
Killip I I III
Randomization arm Ab-BMS Ab-BMS Tir-SES
GP IIb/IIIa inhibitor received Abciximab Abciximab Tirofiban
Implanted stent type/n SES/1 BMS/1 SES/1
Stent diameter 2.25 2.5 2.5
Total stent length, mm 23 23 16
Days after index procedure 1 1 68
Clinical presentation Re-AMI ACS SD
ARC stent thrombosis classification Definite Definite Possible
On thienopiridine*/type Yes/Clo Yes/Clo No
Previous TLR No No No
LVEF at discharge (%) 43 46 40
QCA post-PCI
RVD (mm) 2.20 2.23 2.50
MLD (mm) 1.9 2.18 2.50
Vessel stenosis (%) 26 3 0
QCA at follow-up
RVD (mm) 2.22 2.23 —
MLD (mm) 0 0.02 —
Vessel stenosis (%) 100 98 —
Late loss (mm) 1.9 2.16 —
Whether the patient was taking thienopyridines at the time of the event; †2 additional BMS wer
Ab-BMS  abciximab bare-metal stent; ACS  acute coronary syndrome; ARC  Academic Res
eft anterior descending; LVEF  left ventricular ejection fraction; MLD  minimal lumen diameter
nalysis; RVD  reference vessel diameter; SA  stable angina; SD  sudden death; ST  stent t
target lesion revascularisation; UA  unstable angina followed by Braunwald classification; othyridine discontinuation as compared with the BMS group p11), and 2 meta-analyses suggested a time-dependent
ncrease either in noncardiac mortality (21) or the composite
f total mortality and Q-wave MI in patients treated with
ES compared with BMS (22).
While subject to an ongoing intense debate, current data
mphasize, however, the need to scrutinize long-term out-
ome of all randomized controlled trials of DES versus
MS, especially for those complex lesion/patient subsets
hat were originally excluded from pivotal studies. This may
elp avoid negatively selecting those studies where no excess
f late events is observed (23). Several registries have
eported that DES deployment for ongoing MI or acute
oronary syndrome at presentation is associated with an
ncreased risk of overall ST, especially if complex coronary
esions such as bifurcations are being treated (24,25). This
vidence should be interpreted bearing in mind that the risk
or early (acute and subacute) ST is also known to be
ncreased when BMS are implanted in such conditions (26).
ccordingly, results from randomized controlled trials com-
ossible Stent Thrombosis Up to 2 Year Follow-Up
nfirmed or Possible Stent Thrombosis Up to 2 Year Follow-Up
rmed or Suspected Stent Thrombosis
Late
15 #105 #78 #54 #35 #57
5 81 68 80 32 72
M F M F M M
o Yes No No No No
o Yes No No Yes No
2.3 53 57.6 33.3 61.7 48.7
FX RCA LAD CFX LAD LAD
I I III I I I
-SES Tir-SES Ab-BMS Ab-BMS Ab-BMS Ab-BMS
fiban Tirofiban Abciximab Abciximab Abciximab Abciximab
S/1 SES/2 BMS/2 BMS/1 SES/1 BMS/1
3.0 3.0 3.0 3.0 3.0 2.5
8 40 23 13 28 23
2 128 142 145 176 512
D Re-AMI/D SD Re-AMI Re-AMI/D SD
sible Probable Possible Probable Probable Possible
o No No No Yes/Clo No
o No No No No Yes†
0 30 32 45 40 40
2.18 2.44 2.69 2.50 3.08 2.6
1.90 1.99 2.50 2.23 2.34 1.93
3 18 6 11 24 26
— — — — 2.32
— — — — 0.02
— — — — 99
— — — — 1.91
yed during TLR.
onsortium; Clo  clopidogrel; D  death; GP  glycoprotein; IRA  infarct-related artery; LAD 
percutaneous coronary intervention; PES  paclitaxel-eluting stent; QCA  quantitative coronary
sis; STEMI  ST-segment elevation myocardial infarction; Ticlo  ticlopidine; Tir  tirofiban; TLR
eviations as in Table 1.or P
h Co
Confi
#
6
N
N
8
C
Tir
Tiro
SE
1
11
S
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N
N
4
1
—
—
—
—
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July 10, 2007:138–45 2-Year Outcome of the STRATEGY TrialMS during primary PCI unanimously failed to show an
xcess of ST in the DES arm within 1 year (16,17,27,28).
hether the use of DES during acute MI puts the patient
t increased risk for the occurrence of late ST is unclear.
tent malapposition occurs more frequently during inter-
ention for acute MI. Similarly, thrombus apposed on stents
reates large variations in drug uptake and can act to either
ncrease or decrease wall deposition according to the clot
nd stent geometry (29).
Thus, current data strongly suggest that long-term
ollow-up is needed particularly in this patient/lesion subset
o rule out the possibility of late increase in adverse events in
atients treated with DES.
In the first study to evaluate the benefit of SES assisted by
lycoprotein IIb/IIIa infusion in STEMI patients, a clinical
enefit in terms of reintervention in the previously instru-
ented artery has been reported at 8 months with no excess of
ubacute or late ST compared with BMS (16). In this study
hienopyridine therapy was recommended for at least 3
Figure 2 Event-Free Survival After
Thienopyridine Discontinuation
Cumulative risk of death or nonfatal myocardial infarction after thienopyridine
discontinuation in patients either allocated to receive tirofiban  SES or ab-
ciximab  BMS. (1) Patient #115 experienced a sudden death at home 8 days
after ticlopidine discontinuation. (2) Patient #105 presented 8 days after clopi-
dogrel discontinuation at emergency department with typical chest pain, car-
diogenic shock, and new-onset left bundle branch block. The patient died
immediately after admission, before a diagnostic coronary angiogram could be
obtained. (3) Patient #15 died suddenly at home 22 days after clopidogrel dis-
continuation. (4) Patient #165 died 23 days after ticlopidine discontinuation
from gastric cancer. (5) Patient #42 had a reinfarction 28 days after clopi-
dogrel discontinuation due to an angiographically confirmed disease progres-
sion in the first obtuse marginal branch (the patient underwent intervention in
the left anterior descending artery at the time of index event). (6) Patient #45
was a 78-year-old male with a history of anterior infarction who was treated at the
time of the index procedure for a proximal occlusion of a dominant circumflex
artery who died due to end-stage heart failure 24 days after ticlopidine discontinua-
tion. (7) Patient #94 died 18 days after clopidogrel discontinuation due to chronic
obstructive pulmonary disease. (8) Patient #54 experienced non–Q-wave lateral
myocardial infarction 15 days after clopidogrel discontinuation. The patient
received treatment at the circumflex artery at the time of the index procedure and
refused recatheterization. Abbreviations as in Figure 1.onths, yet the median treatment duration was around 6 conths in both groups. This likely reflects uncertainties in the
edical community regarding optimal duration of long-term
ual antiplatelet treatment after an episode of myocardial
schemia requiring coronary stenting (30). Thus, an extended
linical follow-up appears mandatory to collect information on
he long-term DES safety profile in STEMI patients, espe-
ially after thienopyridine therapy discontinuation.
At 2-year follow-up, the cumulative incidence of MACE
emained lower in the tirofiban  SES group, which was
argely driven by the different rate of TVR. The rate of death
r nonfatal MI was similar in the 2 study groups, and even
hen applying a broad clinical definition of probable or
ossible ST we failed to observe a significant excess of events in
hose patients assigned to receive SES implantation.
On an intention-to-treat basis, the cumulative incidence
f any ST (the sum of definite, probable, or possible)
rended lower in the tirofiban  SES group (from 6.8% to
.4%). This finding was counterbalanced by an opposite
rend at per-stent analysis, with a cumulative rate of ST of
.6% in patients who received SES irrespective of the
riginal randomization scheme as compared with 4.8% in
he BMS group. No episode of ST occurred in the SES
roup beyond 1 year. While not prespecified, the results of
he per-stent analysis may have been biased by the fact that
shift towards SES may have occurred in particularly
omplex lesions in the abciximab  BMS arm. Thus, this
nalysis should be regarded as purely explorative. Indeed, at
er-protocol analysis, there was again no signal towards an
xcess of ST events in the tirofiban  SES arm, which
eems consistent with the protocol-mandated intention-to-
reat analysis. Thus, our data, while not being conclusive,
ail to show a late hazard in the group of patients allocated
o receive SES.
In the PREMIER registry reporting on consecutive
atients treated for acute MI, premature discontinuation of
hienopyridine therapy was frequent and strongly associated
ith subsequent mortality (13).
In the present study, overall there were 8 events, 4 in each
roup, in terms of the composite of death or MI, in the first
0 days after thienopyridine therapy discontinuation.
mong those, 4 events (Patients #115, #105, #15, and #54)
ere highly suspected for ST, 3 of which occurred in the
irofiban  SES group whereas the remaining 1 took place
n a patient allocated to abciximab  BMS. The remaining
deaths (Patients #165, #45, and #94) were related to the
xpected progression of pre-existing morbidity. After inter-
iewing patients’ families, we came to know that therapy
iscontinuation was due to the impossibility to swallow pills
Patient #165) or spontaneous treatment cessation due to
he incoming fatal event (Patients #45 and #94). Thus, in
uch circumstances, thienopyridine withdrawal should be
ikely regarded as an effect more than the cause of the
athological disorder that finally led to fatality. Finally, in
atient #42, it remains possible that clopidogrel withdrawal
ontributed to trigger a nonculprit vessel-related reinfarction.
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2-Year Outcome of the STRATEGY Trial July 10, 2007:138–45Our finding that after thienopyridine discontinuation a
luster of events occurred in both groups was unexpected
nd deserves special attention.
Angiolillo et al. (31) have recently reported a proinflam-
atory and prothrombotic effect after clopidogrel with-
rawal in patients with diabetes after long-term (12
onths) dual antiplatelet therapy. Whether this phenome-
on occurs also in patients without diabetes is currently
nknown. Similarly, whether long-term treatment with
hienopyridines makes patients particularly exposed to
latelet hyperactivity and, as such, to cardiovascular events
fter discontinuation is unclear. This may help explain why
uch a rebound phenomenon has never been described in the
MS era where thienopyridines were recommended for
uch shorter time. At the same time, our analysis also
uggests that thienopyridine withdrawal may partly be the
onsequence more than the cause of conditions in which
eath is expected. This carries relevant implications for a
orrect interpretation of all-comer registries, where a de-
ailed analysis of the cause/effect relationship between
hienopyridine discontinuation and fatal events cannot be
requently carried out. Finally, while unlikely because our
esults were highly consistent with previous findings, we
annot exclude that due to the limited sample size of the
resent study, our findings that a cluster of cardiovascular
vents occurred soon after dual therapy cessation in both
roups may simply reflect a chance finding. Similarly, it
emains theoretically possible that our overall findings may
e confounded by a type II error. Bigger datasets contrasting
ong-term outcome after implantation of both Food and
rug Administration-approved DES versus BMS during
cute MI are in demand to expand and corroborate our
reliminary observations.
Based on available data, it seems reasonable to speculate
hat taking into consideration whether a dual antiplatelet
reatment is still on board or it has been recently discontin-
ed—this may similarly apply to aspirin alone when evalu-
ting very late episodes of possible ST (32)—may help
ncrease the signal-to-noise ratio when a broad clinically
riven definition of confirmed or possible ST is employed,
s has been recently widely suggested.
onclusions
t 2-year follow-up, the cumulative incidence of MACE
emained lower in the tirofiban  SES group, which was
argely driven by the different rate of TVR. The rate of
eath or nonfatal MI was similar in the 2 study groups, and
ven applying a broad clinical definition of possible or
robable ST, we failed to observe an excess of events in
hose patients assigned to receive SES implantation. A clear
luster of events among death or nonfatal MI was, however,
oted in both groups after thienopyridine discontinuation.
n some of the cases (3 in the tirofiban  SES vs. 2 in
bciximab  BMS), a causal link between treatment dis-
ontinuation and the MACE may be suspected whereas inome others this was reasonably ruled out by interviewing
atients’ families. Our findings support the need to design
andomized controlled studies to evaluate the optimal du-
ation of dual antiplatelet treatment in post-MI patients
eceiving DES. Markers of early vulnerability to coronary
vents together with dedicated strategies to avoid the
ebound phenomenon, if any, after thienopyridine discon-
inuation should be similarly investigated.
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